Dr. Devon Christie, MD, is the Medical and Therapeutic Services Director with Numinus Wellness Inc., a Canadian-based company at the forefront of advancing safe, effective and innovative psychedelic-assisted therapies, and a clinical instructor with the UBC Department of Medicine, shares some insights about the therapy and why the U.S. should consider this type of therapy for those who medically qualify and what others can learn from some of Canada’s recent developments.
Dr. Devon Christie, MD, is the Medical and Therapeutic Services Director with Numinus Wellness Inc., a clinical instructor with the UBC Department of Medicine, and has a focused practice in chronic pain. She is a Registered Counsellor emphasizing Relational Somatic Therapy for trauma, and a certified Mindfulness Based Stress Reduction teacher (UCSD) and Interpersonal Mindfulness teacher (UMass). She is trained to deliver both MDMA-assisted therapy for PTSD (MAPS USA) and ketamine-assisted psychotherapy. She is passionate about educating future psychedelic therapists on trauma-informed, relational somatic skills and is a co-founder of the Psychedelic Somatic Psychotherapy training program. She also teaches for the California Institute of Integral Studies (CIIS) Certificate Program in Psychedelic Therapy and Research, the Integrative Psychiatry Institute Certificate Program in Psychedelic Assisted Therapy, and the ONCA Foundation Psychedelic Therapy program. She is currently Principal Investigator and study therapist for a Canadian MAPS-sponsored open-label compassionate access study investigating MDMA-assisted therapy for PTSD, and co-investigator on a study investigating MDMA-assisted therapy for fibromyalgia. Devon is a recognized speaker and expert on the potential for incorporating psychedelic assisted therapies in an improved health care model for the future, and is the Medical and Therapeutic Services Director with Numinus Wellness Inc.